DynamiCure is translating potentially revolutionizing new insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential. We are a team with broad and deep industry experience rapidly advancing multiple candidates towards the clinic.
Our lead program, DC-6001, aims to address the current limitations of today’s most advanced cancer treatments by interferin...
DynamiCure is translating potentially revolutionizing new insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential. We are a team with broad and deep industry experience rapidly advancing multiple candidates towards the clinic.
Our lead program, DC-6001, aims to address the current limitations of today’s most advanced cancer treatments by interfering with the CD93 pathway, a novel mechanism demonstrated to normalize malignant tumor vasculature.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.